Healthcare -
Biotechnology - NASDAQ - US
$ 11.465
-1.16 %
$ 625 M
Market Cap
-6.6
P/E
1. INTRINSIC VALUE
Balance Sheet
Bicara Therapeutics Inc. Common Stock
| Current Assets | 503 M |
| Cash & Short-Term Investments | 490 M |
| Receivables | 0 |
| Other Current Assets | 12.8 M |
| Non-Current Assets | 7.46 M |
| Long-Term Investments | 0 |
| PP&E | 845 K |
| Other Non-Current Assets | 6.62 M |
| Current Liabilities | 18 M |
| Accounts Payable | 3.89 M |
| Short-Term Debt | 607 K |
| Other Current Liabilities | 13.5 M |
| Non-Current Liabilities | 131 K |
| Long-Term Debt | 131 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Bicara Therapeutics Inc. Common Stock
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 82.4 M |
| Operating Income | -82.4 M |
| Other Expenses | -14.4 M |
| Net Income | -68 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Bicara Therapeutics Inc. Common Stock
| Net Income | -68 M |
| Depreciation & Amortization | 56 K |
| Capital Expenditures | -71 K |
| Stock-Based Compensation | 7.4 M |
| Change in Working Capital | -14.1 M |
| Others | -14.2 M |
| Free Cash Flow | -74.8 M |
Wall Street Analysts Price Targets
Bicara Therapeutics Inc. Common Stock
Wall Street analysts predict an average 1-year price target for BCAX of $30.3 , with forecasts ranging from
a
low of
$8 to a high of $48 .
BCAX Lowest Price Target
Wall Street Target
8 USD
-30.22%
BCAX Average Price Target
Wall Street Target
30.3 USD
164.57%
BCAX Highest Price Target
Wall Street Target
48 USD
318.67%
4. DIVIDEND
ANALYSIS
BCAX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Bicara Therapeutics Inc. Common Stock
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.02 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
33.6 M USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that members of management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 3:20 p.m. ET.
globenewswire.com
- 1 week ago
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast today at 3:00 p.m. CT / 4:00 p.m.
globenewswire.com
- 2 weeks ago
Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity
The recent stock drop in Bicara Therapeutics Inc. is an overreaction, as the full phase 1/1b data—including key OS results—has yet to be released. BCAX interim data for FICERA plus KEYTRUDA in HPV-negative HNSCC patients showed a 64% ORR, exceeding historical benchmarks and highlighting a significant unmet need. Upcoming ASCO 2025 data and FDA alignment on Accelerated Approval using ORR as an endpoint create a compelling near-term catalyst for investors.
seekingalpha.com
- 3 weeks ago
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset
globenewswire.com
- 3 weeks ago
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Enrollment ongoing in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Strong financial position with approximately $462 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the first quarter ended March 31, 2025 and provided a business update. "We continued to execute across our clinical programs in the first quarter, maintaining strong momentum as we advance FORTIFI-HN01, the pivotal Phase 2/3 trial of ficerafusp alfa in HPV-negative recurrent/metastatic head and neck squamous cell carcinoma," said Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics.
globenewswire.com
- 1 month ago
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced multiple presentations related to ficerafusp alfa at the American Association for Cancer Research (AACR) Annual Meeting 2025. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) and is being evaluated across multiple solid tumor types.
globenewswire.com
- 1 month ago
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that updated data from the company's ongoing Phase 1/1b clinical trial of ficerafusp alfa in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) will be highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 30-June 3, 2025 in Chicago, IL. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) and is being evaluated across multiple solid tumor types.
globenewswire.com
- 1 month ago
Bicara: Innovative Precision Tumor Targeting
Bicara Therapeutics' lead candidate, ficerafusp alfa, targets EGFR and TGF-beta in tumors, showing promise in hard-to-treat cancers like Head and Neck Squamous Cell Carcinoma. Bicara's financial health is robust, with $489.7 million in cash, ensuring operations through mid-2029, bolstered by a successful IPO and Series C funding. Early clinical data for ficerafusp alfa plus pembrolizumab in HPV-negative HNSCC shows significant antitumor activity and manageable safety, supporting its potential market impact.
seekingalpha.com
- 1 month ago
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Dosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Strong financial position with approximately $490 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. “2024 was a remarkable year for Bicara, marked by our successful transition to a public company, the advancement of our lead asset, ficerafusp alfa, and the addition of key leaders to our executive team and Board of Directors.
globenewswire.com
- 2 months ago
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that three abstracts relating to the company's lead product candidate, ficerafusp alfa, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will be held from April 25-30, 2025 in Chicago, IL. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) and is being evaluated across multiple solid tumor types.
globenewswire.com
- 2 months ago
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 3:10 p.m. ET.
globenewswire.com
- 3 months ago
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β).
globenewswire.com
- 4 months ago
8. Profile
Summary
Bicara Therapeutics Inc. Common Stock BCAX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 625 M
Dividend Yield
0.00%
Description
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Contact
116 Huntington Avenue, Boston, MA, 02116
https://www.bicara.com
IPO
Date
None
Employees
55
Officers
Ms. Sathish Hasige Ph.D.
Senior Vice President and Head of Technical Operations & Supply Chain
Mr. Ryan Cohlhepp Pharm.D.
President, Chief Operating Officer & Director
Ms. Lara S. Meisner J.D.
Chief Legal Officer & Corporate Secretary
Dr. Jeltje Schulten M.B.A., M.D.
Senior Vice President of Clinical & Medical Affairs
Ms. Rachel Salazar
SVice President of R&D Strategy and Operations
Mr. Jean-Paul Rodrique
Senior Vice President & Global Head of Quality Assurance
Ms. Claire Mazumdar Clemon M.B.A., Ph.D.
Chief Executive Officer & Director
Dr. David Raben M.D.
Chief Medical Officer
Ms. Angela Windt
Vice President & Head of Regulatory Affairs
Mr. Ivan Hyep M.B.A.
Chief Financial Officer